Navigation Links
First Swedish Patients Receive MitraClip(R) Therapy
Date:8/24/2009

MENLO PARK, Calif., Aug. 24 /PRNewswire/ -- Evalve, Inc., the leader in the development of devices for the percutaneous repair of cardiac valves, today announced treatment of the first group of patients with the MitraClip(R) system at the Karolinska University Hospital in Solna, Stockholm, Sweden. The MitraClip(R) system is the only medical device commercially available in the European Union which provides a non-surgical mitral valve repair option for patients suffering from the effects of functional and degenerative mitral regurgitation (MR).

MR is the most common type of heart valve insufficiency in Europe and the United States, affecting millions of people worldwide. Significant MR affects more than eight million people in the U.S. and Europe, the majority of which have FMR. There are more than 600,000 new diagnoses of significant MR each year in Europe and the U.S.; however, only 20 percent of these patients undergo surgery each year. Many higher risk surgical patients and non-surgical patients continue to be affected by the chronic volume overload caused by MR, which requires the heart to work harder, and may ultimately lead to heart failure.

The first patients in Sweden were successfully treated by a team led by cardio-thoracic surgeon Anders Jonsson, M.D., Ph.D., assisted by interventional cardiologist Magnus Settergren, M.D., Ph.D. Echocardiography was performed by cardiac anesthetist Jan Hultman, M.D., Ph.D. and clinical cardiologist Reidar Winter, M.D., Ph.D.

"The MitraClip(R) technology has added a new dimension to the treatment of mitral regurgitation. In my initial experience with our first three patients, I was very pleased to see the good result achieved with a single clip in each of our patients. Any less invasive approach for heart valve procedures is worthwhile to consider, especially if the long term results are compatible with the techniques requiring an open thorax. I am looking forward to treat more patients to further evaluate this approach," said Dr. Hultman, Director of the Clinic in Cardiothoracic Surgery and Anesthesia. "It is very satisfactory for us as a unit to be able to offer this technology to some of our patients. The MitraClip(R) is a device that hopefully will enable us to design the optimal treatment for all different types of patients with MR including high risk and inoperable candidates," added Dr. Jonsson who led the team.

Evalve initiated commercial sales of the MitraClip(R) system in Europe under the CE Mark in late 2008. The company is employing a direct sales strategy and is taking a disciplined and measured approach to the initial commercial roll out. Evalve has worked closely with hospitals to deliver high quality training programs in preparation for the first series of implants and offers ongoing support. The MitraClip(R) device is currently being implanted in six Western European countries, including Germany, Italy, the United Kingdom, the Netherlands, Switzerland and now Sweden.

"We are very pleased with the successful initial use of the MitraClip(R) device in Sweden at this outstanding cardiac center," said Ferolyn Powell, president and chief executive officer of Evalve. "It is noteworthy that the MitraClip(R) therapy can be delivered to patients by both interventional cardiologists and cardiothoracic surgeons in close collaboration with their colleagues in echocardiology. The centers offering the MitraClip(R) therapy in Europe are pioneering a new field and era in the medical care for patients who suffer from mitral regurgitation, especially for those who, until now, had very limited therapeutic options."

About the MitraClip(R) Procedure

Percutaneous mitral repair with Evalve's MitraClip(R) device is performed by physicians in the catheterization laboratory. The heart beats normally during the procedure, and therefore does not require a heart-lung bypass machine. In addition to improving blood flow through the heart, the procedure may also relieve symptoms such as fatigue and shortness of breath that often affect patients with significant MR. After treatment, patients generally recover quickly. The MitraClip(R) device may improve quality of life and may help MR patients avoid or delay surgery, having preserved surgical options (valve repair or replacement) should surgery become necessary.

About Evalve, Inc.

Founded in 1999, Evalve, Inc., headquartered in Menlo Park, Calif., has developed a proprietary system which enables percutaneous repair of cardiac valves. The company's initial products are intended to reduce the risks, trauma and costs associated with current open, arrested heart surgical options. For more information about Evalve, Inc., and for an animated explanation of the procedure using the MitraClip(R) device, visit www.evalveinc.com. Evalve is the first portfolio company from the medical device company incubator, The Foundry (www.thefoundry.com).

The MitraClip(R) system is currently undergoing clinical evaluation in the United States and Canada.

MitraClip(R) and Evalve(R) are registered trademarks of Evalve, Inc.

    Media Contact:
    Amy Hytowitz
    Edelman
    1-323-202-1028
    Amy.Hytowitz@edelman.com


'/>"/>
SOURCE Evalve, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Integrated Medical Systems Receives $1.1 Million From the U.S. Department of Defense for Critical Enhancements of the Worlds First Suitcase Intensive Care Unit
2. Mount Sinai first with new technique to prevent a major cause for heart-related stroke
3. School Kids, Parents Should Get Flu Vaccines First
4. Tevas Patient First Initiative Highlights Struggle Against High Health Care Costs, Reminds Lawmakers of Reform Goals
5. 49 Companies Submit Products for First Spine Technology Awards; Entries Now Closed
6. MN Community Measurement Launches First-Of-Its-Kind Quality Measure For Depression Care
7. National Practice Transition Network Attracting National Attention as the Country's First Membership-Based, Commission-Free Dental Practice Transition Company
8. Cyberonics Reports Strong Fiscal 2010 First Quarter Results
9. A UK Cosmetic Surgery First: An Eyelash Transplant Procedure
10. Mylans Matrix Receives First and Only Tentative FDA Approval Under PEPFAR for Generic Version of Atripla(R) HIV Treatment
11. CA$H-First(SM) LTCi Provides First-Day Cash Benefits at Affordable Rates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... ... The Radiology Business Management Association (RBMA) has named the nine winners ... year, are among the most prestigious in radiology marketing because a panel of radiology ... recognize achievements in both large budget (over $5,000) and small budget (under $5,000) campaigns. ...
(Date:3/24/2017)... MI (PRWEB) , ... March 24, 2017 , ... ... assistance, financial planning, and related services to families and business owners across eastern ... aimed at feeding regional families struggling with financial difficulties. , The Oxford/Orion FISH ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... announce that they are now offering treatments for sleep apnea and TMJ at ... offices. Sleep apnea , specifically the obstructive type, is increasingly being treated ...
(Date:3/24/2017)... FL (PRWEB) , ... March 24, 2017 , ... ... Inc. ( http://www.hygieacare.com ) announced their partnership to prep patients for colonoscopy at ... Endoscopy Centers in 87th Ave., Miami, FL. , The HyGIeaCare® ...
(Date:3/24/2017)... ... March 24, 2017 , ... “End Time GPS”: a dauntless and ... “End Time GPS” is the creation of published author, Wesley Gerboth, a World ... military munitions and space-vehicle projects. Now, at age ninety-one, he shares the Wisdom God ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... , March 24, 2017   The Accreditation ... within medical affairs in the pharmaceutical industry has ... chair of a newly formed scientific advisory board. ... to form the first ever medical affairs think ... more information about the ACMA, please visit  www.medicalaffairsspecialist.org ...
(Date:3/24/2017)... Research and Markets has announced the addition of ... to their offering. ... IPF pipeline is very strong with a total of 97 drug candidates. ... and Sanofi are involved in the development of the IPF therapeutics. The ... Phase III stage, 15 are in Phase II stage, 12 are in ...
(Date:3/24/2017)... 2017 Today Stock-Callers.com have issued research ... Neovasc Inc. (NASDAQ: NVCN), Hologic Inc. (NASDAQ: HOLX), Edwards Lifesciences ... SSH ). These companies are part of the Healthcare sector, ... March 23 rd , 2017, with the NYSE Health Care ... care companies in the S&P 500 were down about 0.4% ...
Breaking Medicine Technology: